A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling

Gut

Volumn 65, Issue 4, 2016, Pages 647-657

  Kong, Bo ^a   Wu, Weiwei ^a   Cheng, Tao ^a   Schlitter, Anna Melissa ^a   Qian, Chengjia ^a   Bruns, Philipp ^a,b   Jian, Ziying ^a   Jäger, Carsten ^a   Regel, Ivonne ^a   Raulefs, Susanne ^a   Behler, Nora ^a   Irmler, Martin ^b   Beckers, Johannes ^a,b,c   Friess, Helmut ^a   Erkan, Mert ^d   Siveke, Jens T ^a   Tannapfel, Andrea ^e   Hahn, Stephan A ^e   Theis, Fabian J ^b   Esposito, Irene ^a   Kleeff, Jörg ^a   Michalski, Christoph W ^f   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d KOÇ UNIVERSITY   (Turkey)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ALDH1A3; PROTEIN KINASE B; TUMOR MARKER; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; KRAS2 PROTEIN, MOUSE; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; TARGET OF RAPAMYCIN KINASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ERK ONCOGENE; FEMALE; HAPLOINSUFFICIENCY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MEK ONCOGENE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TSC1 GENE; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARCINOGENESIS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ADENOCARCINOMA; ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84961989770     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307616     Document Type: Article

References (38)

1. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500.
2. Russo M, Di Nicolantonio F, Bardelli A. Climbing RAS, the everest of oncogenes. Cancer Discov 2014;4:19-21.
3. Ying H, Elpek KG, Vinjamoori A, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 2011;1:158-69.
4. Eser S, Reiff N, Messer M, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013;23:406-20.
5. Ardito CM, Gruner BM, Takeuchi KK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012;22:304-17.
6. Navas C, Hernandez-Porras I, Schuhmacher AJ, et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:318-30.
7. Liang MC, Ma J, Chen L, et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010;29:1588-97.
8. Guo Y, Chekaluk Y, Zhang J, et al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol 2013;230:17-27.
9. Kennedy AL, Morton JP, Manoharan I, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011;42:36-49.
10. Javle MM, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer 2010;10:368.
11. Soares HP, Ni Y, Kisfalvi K, et al. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE 2013;8:e57289.
12. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-8.
13. Morran DC, Wu J, Jamieson NB, et al. Targeting mTOR dependency in pancreatic cancer. Gut 2014;63:1481-9.
14. Hahn SA, Seymour AB, Hoque AT, et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995;55:4670-5.
15. Munding JB, Adai AT, Maghnouj A, et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 2012;131:E86-E95.
16. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
17. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
18. Ma L, Teruya-Feldstein J, Bonner P, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007;67:7106-12.
19. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005;8:185-95.
20. Al-Ghamdi S, Albasri A, Cachat J, et al. Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PLoS ONE 2011;6:e20919.
21. Al-Ghamdi S, Cachat J, Albasri A, et al. C-Terminal Tensin-like gene functions as an oncogene and promotes cell motility in pancreatic cancer. Pancreas 2013;42:135-40.
22. Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:105-20.
23. Panarelli NC, Yantiss RK, Yeh MM, et al. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol 2012;138:211-22.
24. Su MC, Yuan RH, Lin CY, et al. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 2008;21:1379-86.
25. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53.
26. Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res 2007;67:9704-12.
27. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149:656-70.
28. Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340-51.
29. Kahlert C, Bergmann F, Beck J, et al. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer 2011;11:275.
30. Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013;110:8644-9.
31. Mann KM, Ward JM, Yew CC, et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2012;109:5934-41.
32. Perez-Mancera PA, Rust AG, van der Weyden L, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012;486:266-70.
33. Weissmueller S, Manchado E, Saborowski M, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014;157:382-94.
34. Black W, Vasiliou V. The aldehyde dehydrogenase gene superfamily resource center. Hum Genomics 2009;4:136-42.
35. Marcato P, Dean CA, Giacomantonio CA, et al. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378-84.
36. Rovira M, Scott SG, Liss AS, et al. Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci USA 2010;107:75-80.
37. Ioannou M, Serafimidis I, Arnes L, et al. ALDH1B1 is a potential stem/progenitor marker for multiple pancreas progenitor pools. Dev Biol 2013;374:153-63.
38. Molotkov A, Molotkova N, Duester G. Retinoic acid generated by Raldh2 in mesoderm is required for mouse dorsal endodermal pancreas development. Dev Dyn 2005;232:950-7.